SCHEMBL2274223

SCHEMBL2274223

Cc1cccc(C(=O)Nc2cc(-c3ccc4c(c3)OCO4)ccc2C(=O)O)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
KDM4E B2RXH2 3/20 0.53
NPC1 O15118 7/20 0.52
RAB9A P51151 4/20 0.52
TP53 P04637 3/20 0.52
HPGD P15428 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
FABP3 P05413 1/20 0.50
FABP4 P15090 1/20 0.50
FABP5 Q01469 1/20 0.50
HTT P42858 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
NPSR1 Q6W5P4 2/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12394969 0.90 NPC1 (0.55) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL12394970 0.87 ALDH1A1 (0.51) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL2272608 0.86 ALDH1A1 (0.47) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL2275722 0.84 ACLY (0.57) KDM4ENPC1RAB9ATP53FABP4
SCHEMBL2278464 0.82 ACLY (0.49) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL2274795 0.82 NPC1 (0.60) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL2272541 0.80 PTGS2 (0.63) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL2276321 0.80 ACLY (0.56) NPC1RAB9AGRIK1
SCHEMBL2273182 0.77 PTGS2 (0.66) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL2272852 0.76 CASP3 (0.57) ALDH1A1KDM4ENPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ALDH1A1 645/4885KDM4E 1257/4885NPC1 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.